Health Care Stocks Outperform Tech: Key Earnings Insights
Tech had a rough week. Health care earnings did not.
Of 23 S and P 500 health care companies reporting last week, 22 beat EPS estimates and all 23 grew revenue year over year.
Here are 4 worth researching. 👇
📌 The Watchlist
1. AbbVie | $ABBV: Drugmaker known for immunology and neuroscience medicines. Q3 revenue was $17.40 billion, up 10.3 percent year over year, adjusted EPS was $3.82, and it raised 2026 adjusted EPS guidance to $13.95 to $13.99, with Skyrizi sales up 22.7 percent to $5.78 billion.
2. Gilead Sciences | $GILD: Maker of HIV and antiviral medicines. Q3 revenue was $8.30 billion, up 7 percent year over year, adjusted EPS was $2.55, and it raised full year 2026 product sales guidance to $31.0 billion to $31.3 billion, with HIV sales up 18 percent to $6.2 billion.
3. Incyte | $INCY: Biotech focused on cancer and immune diseases, led by Jakafi and Opzelura. Q3 total revenue was $1.56 billion, up 14 percent year over year, and it raised 2026 total net sales guidance to $5.21 billion to $5.30 billion, with Opzelura sales up 36 percent to $255 million.
4. Bristol Myers Squibb | $BMY: Drugmaker with cancer, immunology and heart medicines. Q3 revenue was $13.07 billion, up 7 percent year over year, and adjusted EPS was $1.35, topping the $1.09 estimate.
📌 The Part Worth Saving
A beat is a reason to research a stock. It is not a reason to buy blindly.
Look for:
- Revenue growth with the beat, not cost cuts alone
- Guidance raised, not just a one quarter beat
- One time charges separated from the core business, like Incyte's Vega acquisition charge
- Patent and pricing risks still in view, like Gilead's disclosed Biktarvy Medicare price cut starting in 2028
- What the next report must repeat for the beat to hold
The best question: Which of these beats looks repeatable next quarter, and which was a one time lift?
Education only, not financial advice.